Phase I, dose-escalating study to assess the safety and tolerability of CERE-110 in subjects with mild to moderate Alzheimer's disease.
Phase of Trial: Phase I
Latest Information Update: 02 Nov 2016
At a glance
- Drugs CERE 110 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Ceregene
- 01 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Apr 2009 Additional lead trial investigator 'Joao Siffert' added as reported by ClinicalTrials.gov.
- 10 Aug 2008 The expected completion date for this trial is now 1 May 2010 according to clinicaltrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History